Phase II Study of Topotecan and Bevacizumab in Advanced, Refractory Non—Small-Cell Lung Cancer

Second-line therapies for non—small-cell lung cancer (NSCLC) provide modest disease control. Weekly topotecan in combination with bevacizumab was evaluated in advanced, refractory NSCLC. Median progression-free survival was 5.1 months and overall survival was 11.5 months. Based on its favorable dise...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Lung Cancer
Huvudupphovsmän: Powell, Steven F., Beitinjaneh, Amer, Tessema, Mathewos, Bliss, Robin L., Kratzke, Robert A., Leach, Joseph, Dudek, Arkadiusz Z.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2013
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4524809/
https://ncbi.nlm.nih.gov/pubmed/23816875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2013.04.009
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk